Portage Biotech is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Portage Biotech's Cash And Short Term Investments are most likely to increase significantly in the upcoming years. The Portage Biotech's current Common Stock Shares Outstanding is estimated to increase to about 24.6 M, while Total Stockholder Equity is projected to decrease to roughly 4.4 M. Key indicators impacting Portage Biotech's financial strength include:
The essential information of the day-to-day investment outlook for Portage Biotech includes many different criteria found on its balance sheet. An individual investor should monitor Portage Biotech's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Portage Biotech.
Portage Biotech competes with Amylyx Pharmaceuticals, Blueprint Medicines, Arvinas, Aerovate Therapeutics, and Anebulo Pharmaceuticals. Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. It also provides Nanolipogel co-formulation platform for delivery of DNA aptamers and certain aptamer-small molecule-based combination products and STING agonist platform, a proprietary immune priming and boosting technology, offers various ways to target immune stimulation towards the cancer, as well as to co-deliver various signals in a single product. Portage Biotech is traded on NASDAQ Exchange in the United States.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Portage Biotech's current stock value. Our valuation model uses many indicators to compare Portage Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Portage Biotech competition to find correlations between indicators driving Portage Biotech's intrinsic value. More Info.
Portage Biotech is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Portage Biotech's Return On Equity is most likely to decrease significantly in the upcoming years. Comparative valuation analysis is a catch-all technique that is used if you cannot value Portage Biotech by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Portage Biotech Systematic Risk
Portage Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Portage Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Portage Biotech correlated with the market. If Beta is less than 0 Portage Biotech generally moves in the opposite direction as compared to the market. If Portage Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Portage Biotech is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Portage Biotech is generally in the same direction as the market. If Beta > 1 Portage Biotech moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Portage Biotech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Portage Biotech's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Portage Biotech growth as a starting point in their analysis.
Price Earnings To Growth Ratio
0.0759
At this time, Portage Biotech's Price Earnings To Growth Ratio is most likely to slightly decrease in the upcoming years.
Portage Biotech March 21, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Portage Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Portage Biotech. We use our internally-developed statistical techniques to arrive at the intrinsic value of Portage Biotech based on widely used predictive technical indicators. In general, we focus on analyzing Portage Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Portage Biotech's daily price indicators and compare them against related drivers.
When running Portage Biotech's price analysis, check to measure Portage Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Portage Biotech is operating at the current time. Most of Portage Biotech's value examination focuses on studying past and present price action to predict the probability of Portage Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Portage Biotech's price. Additionally, you may evaluate how the addition of Portage Biotech to your portfolios can decrease your overall portfolio volatility.